



News Release

Suven Life Sciences bags Pharmexcil's "Gold Patent Award"

HYDERABAD, INDIA (Sept 28, 2015) – Suven Life Sciences Ltd (SUVEN) announces today that they bagged Pharmexcil's "Gold Patent Award" for securing the most number of product patents **under NCE category**. The Awards were presented during the "Awards Function for Exports and patents during 11Th Annual General Meet of Pharmexcil at Hyderabad".

Suven secured 77 product patents for their NCE's during 2014-2015 from several countries including all the developed countries like USA, Europe, Japan, Australia and Canada etc. So far Suven secured a total of 753 product patents globally for their NCE's and 37 process patents.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.**

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;